ABT

EX-99.1

2 abt-2026q2xexhibitx991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

–Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent

–Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31

–Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1

–Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58

–Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

ABBOTT PARK, Ill., July 16, 2026 — Abbott today announced financial results for the second quarter ended June 30, 2026.

•Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.

•Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.

•Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.

•Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.

•In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.

•In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.

•In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.

•In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device.

•In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.

"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."

Page 1 of 21

SECOND-QUARTER BUSINESS OVERVIEW

Comparable sales growth:

Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Second Quarter 2026 Results (2Q26)

Sales 2Q26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices

U.S.5,216 871 1,660 — 2,680

International7,377 1,273 1,432 1,499 3,173

Total reported12,593 2,144 3,092 1,499 5,853

% Change vs. 2Q25

U.S.22.0 (9.0)104.8 n/a7.0

International7.5 1.4 5.1 8.4 10.7

Total reported13.0 (3.1)42.3 8.4 9.0

Total reported excl. foreign exchange impact12.2 (3.6)41.3 8.7 7.9

Comparable sales growth4.8 (3.6)2.9 8.7 8.4

U.S.3.5 (9.0)4.0 n/a8.0

International5.8 0.6 1.6 8.7 8.7

First Half 2026 Results (1H26)

Sales 1H26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices

U.S.9,490 1,715 2,565 — 5,203

International14,267 2,446 2,707 2,925 6,189

Total reported23,757 4,161 5,272 2,925 11,392

% Change vs. 1H25

U.S.12.4 (10.3)52.5 n/a7.4

International9.3 — 6.4 10.7 14.2

Total reported10.5 (4.5)24.7 10.7 11.0

Total reported excl. foreign exchange impact8.2 (5.6)22.4 8.9 8.0

Comparable sales growth4.3 (5.6)2.4 8.9 8.4

U.S.3.0 (10.3)3.0 n/a8.3

International5.3 (1.9)1.6 8.9 8.5

Refer to pages 16 and 17 for a reconciliation of comparable

EX-99.1

2 abt-2026q1xexhibitx991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

–First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent

–Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market

–Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1

–Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences

ABBOTT PARK, Ill., April 16, 2026 — Abbott today announced financial results for the first quarter ended March 31, 2026.

•First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.

•First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.

•On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.

•Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.

•Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

•In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.

•In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).

•In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre® achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.

"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."

Page 1 of 15

FIRST-QUARTER BUSINESS OVERVIEW

Comparable sales growth:

Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices

U.S.4,274 844 905 — 2,523

International6,890 1,173 1,275 1,426 3,016

Total reported11,164 2,017 2,180 1,426 5,539

% Change vs. 1Q25

U.S.2.5 (11.6)3.8 n/a7.9

International11.3 (1.5)7.8 13.2 18.0

Total reported7.8 (6.0)6.1 13.2 13.2

Total reported excl. foreign exchange impact3.8 (7.7)2.5 9.0 8.1

Comparable sales growth3.7 (7.7)1.8 9.0 8.5

U.S.2.5 (11.6)2.0 n/a8.7

International4.6 (4.7)1.6 9.0 8.3

Refer to page 13 for a reconciliation of comparable sales growth.

Page 2 of 15

Nutrition

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions) TotalPediatricAdult

U.S.844 511 333

International1,173 442 731

Total reported2,017 953 1,064

% Change vs. 1Q25

U.S.(11.6)(13.0)(9.2)

International(1.5)(2.6)(0.9)

Total reported(6.0)(8.5)(3.6)

Total reported excl. foreign exchange impact(7.7)(9.7)(5.9)

Comparable sales growth(7.7)(9.7)(5.9)

U.S.(11.6)(13.0)(9.2)

International(4.7)(5.3)(4.3)

Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing act

abt-202601220000001800FALSENew York Stock ExchangeCHX00000018002026-01-222026-01-220000001800exch:XCHI2026-01-222026-01-220000001800exch:XNYS2026-01-222026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

Illinois1-218936-0698440 (State or other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification  No.)

100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (224) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered

Common Shares, Without Par ValueABTNew York Stock Exchange NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition On January 22, 2026, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, legal reserves, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01    Financial Statements and Exhibits

Exhibit No.Exhibit

99.1 Press Release dated January 22, 2026 (furnished pursuant to Item 2.02).

104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES

Date: January 22, 2026By:/s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer